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Objective: Patency rates for autogenous accesses are presumed to be better than for polytetrafluoroethylene (PTFE)
accesses, although the strength of the supporting evidence is limited. We undertook this study to test the hypothesis that
patency rates for upper extremity autogenous hemodialysis arteriovenous accesses in adults are superior to those for PTFE
counterparts.
Methods: A systematic review of relevant literature and meta-analysis of the patency data were performed. Studies were
considered acceptable if patency data were reported by either life table or Kaplan-Meier method, including number of
patients at risk.
Results: The thirty-four studies that satisfied the inclusion criteria were composed predominantly of case series or
nonrandomized controlled studies; no randomized, controlled studies comparing autogenous and PTFE accesses were
included. The primary patency rate for autogenous accesses was 72% (95% confidence interval [CI], 70%-74%) at 6
months and 51% (95% CI, 48%-53%) at 18 months, and the corresponding primary patency rate for PTFE accesses was
58% (95% CI, 56%-61%) and 33% (95% CI, 31%-36%), respectively. The secondary patency rate for autogenous accesses
was 86% (95% CI, 84%-88%) at 6 months and 77% (95% CI, 74%-79%) at 18 months, and the corresponding secondary
patency rate for PTFE accesses was 76% (95% CI, 73%-79%) and 55% (95% CI, 51%-59%), respectively.
Conclusions: The patency rate for autogenous upper extremity arteriovenous hemodialysis accesses in adults is superior to
that for PTFE counterparts, although the overall quality of the studies in the meta-analysis was less than ideal.
Randomized, controlled studies to further examine the differences in outcome between these two access types are
necessary. (J Vasc Surg 2003;38:1005-11.)
The consensus among physicians who care for patients
with end-stage renal disease is that the patency rates for
autogenous arteriovenous hemodialysis accesses are supe-
rior to those for prosthetic counterparts. Indeed, the Na-
tional Kidney Foundation Clinical Guidelines for Vascular
Access (NKF/DOQI) recommend autogenous radioce-
phalic and brachiocephalic accesses as the first and second
choices, respectively, for permanent access, and these rec-
ommendations are based in part on their presumed superior
patency rates.1 In addition, the NKF/DOQI also state that
the center-specific thrombosis rates for autogenous ac-
cesses should be lower than for prosthetic accesses (0.25
episodes per patient per year vs 0.50 episodes per patient
per year). However, the quality of the evidence supporting
superior patency of autogenous arteriovenous accesses ref-
erenced by the NKF/DOQI is limited, and includes retro-
spective case series2,3 and expert opinions.4,5 Furthermore,
the opinion that the patency rate for autogenous arterio-
venous accesses is superior to their prosthetic counterparts
is not universal. Hodges et al6 reviewed the outcome of all
dialysis access procedures performed over several years and
reported that patency rate for autogenous and prosthetic
arteriovenous accesses was similar, although significantly
less than for peritoneal catheters. It is likely that the uncer-
tainty about the patency of various access types contributed
to the finding that only 17% of new hemodialysis access
procedures performed in the United States among Medi-
care patients during 1996-1997 were autogenous access-
es.7
This study was designed to test the hypothesis that the
patency rate for upper extremity autogenous hemodialysis
arteriovenous accesses in adults is superior to that for their
polytetrafluoroethylene (PTFE) counterparts, using the
best available evidence in the literature identified with a
systematic review.
METHODS
Search strategy. The MEDLINE electronic database
for 1966 to July 2001 was searched with PubMed (US
National Library of Medicine, Bethesda, Md), with the
terms hemodialysis access, arteriovenous fistula, arterio-
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venous graft, arteriovenous shunt, and access surgery, in
conjunction with the terms life table and Kaplan-Meier.
The titles and available abstracts of the articles identified in
the MEDLINE search were then reviewed, and relevant
articles were identified for further in-depth review. The
bibliographies of these articles identified by MEDLINE for
further in-depth review, the bibliographies from the clinical
practice guidelines from NKF/DOQI and the Canadian
Society for Nephrology, and the bibliographies from sev-
eral hemodialysis access, vascular surgical, and general sur-
gical textbooks were searched individually to identify addi-
tional relevant articles (Appendix 1, online only). These
relevant articles identified by the hand search were subse-
quently found on MEDLINE by searching by author
names, and similar criteria were used to determine whether
they merited further in-depth review. The searches were
limited to full-text articles published in English, although
studies were not specifically excluded on the basis of exper-
imental design. All searches were performed by a single
author (T.S.H.), with the assistance of the University of
Florida Health Science Center librarians.
Study criteria. Analysis was restricted to studies that
documented the patency of upper-extremity autogenous or
PTFE arteriovenous accesses by using either life table or the
Kaplan-Meier method, and that included the number of
patients at risk. Patency was defined as ability to successfully
dialyze through the access, and is clinically different from a
patent, nonfunctional access. Data reported in both tabular
and graphic form were considered acceptable if all initial
patients were accounted for and the data could be con-
verted into the standard life table format, as recommended
by the national vascular surgical societies.8 The analysis was
limited to studies that encompassed predominantly adults
(age, 17 years), although no other demographic data,
comorbid conditions, or past medical events were factored
into the inclusion criteria. All possible upper extremity
autogenous and PTFE access configurations (eg, radioce-
phalic, brachiobasilic) were included. Furthermore, all
types of PTFE grafts were included, regardless of manufac-
turer (Impra, C. R. Bard, Murray Hill, NJ; W. L. Gore and
Associates, Flagstaff, Ariz) or fabric characteristics (eg,
standard wall, thin wall, stretch), although composite vein
and prosthetic configurations, such as those that incorpo-
rate a venous anastomotic cuff, were excluded. Accesses
constructed with biologic grafts (eg, bovine carotid artery),
alternative prosthetic grafts (eg, Dacron, silicone-coated),
and translocated, autogenous saphenous vein grafts were
specifically excluded from the analysis. Studies confounded
by comparisons with these alternative graft types were
included, although the data extracted were limited to au-
togenous and PTFE accesses. Only the most recent publi-
cation was included from an institution when serial publi-
cations encompassing some of the same patients were
identified.
Study review and data extraction. Two reviewers
(T.S.H., J.M.S.) independently evaluated the 211 full-text
articles identified in the searches to identify those that
satisfied the inclusion criteria. Data were extracted from the
acceptable articles, and differences of opinion between
reviewers were resolved by consensus. Data extracted in-
cluded details of study design, access configuration, patient
demographic data, perioperative outcome, and patency.
Perioperative outcome measures included mortality and
the complications of graft infection, hand ischemia, and
aneurysm or pseudoaneurysm formation. These complica-
tions were defined by using the conventions in the individ-
ual articles because no standard reporting system was avail-
able at the time of their publication. The patency data
extracted comprised relevant components of life table and
the Kaplan-Meier method, including time interval, number
of patients at risk, interval failures, and interval withdrawals.
Patency data were extracted for both access types (autoge-
nous, PTFE), patency assessments (primary, secondary),
and anatomic location (upper arm, forearm), when re-
ported in individual studies. Primary patency was defined as
the functional access patency until any type of intervention
(eg, balloon angioplasty, patch angioplasty); secondary pa-
tency was defined as the functional access patency until
either final failure or the access was abandoned. Demo-
graphic and outcome data were extracted only for subsets
of patients included in the study. Often it was impossible to
extract these data because they were not differentiated by
autogenous or PTFE access type but were presented
together.
Statistical analysis. Separate life tables were con-
structed for every access type (PTFE, autogenous), patency
assessment (primary, secondary), and anatomic location
(forearm, upper arm) reported in the individual studies (eg,
forearm/PTFE/secondary patency). This required con-
verting the data from Kaplan-Meier format to life table
format in a subset of individual studies. Simple compilation
of these separate life tables into larger, aggregate life tables
for the various access types/patency assessments/anatomic
locations by adding the number of patients at risk, failures,
and interval withdrawals was not possible because the time
intervals used in the individual studies varied, with the most
common being 3, 6, or 12 months. To overcome this
limitation, the individual studies for the various access
types/patency assessments/anatomic locations in which
the life tables were reported in 3-month intervals were
aggregated into a single 3-month interval table by adding
the number of patients at risk, interval failures, and interval
withdrawals. Studies for the various access types/patency
assessments/anatomic locations reporting patency at
6-month intervals were similarly combined to create a
single 6-month interval life table. Of note, the 6-month
interval life table also included data from the 3-month
interval table, because the interval from 0 to 6 months (first
interval for the 6-month interval life table) is the same as the
sum of the intervals from 0 to 3 months and 3 to 6 months
(first two intervals for the 3-month interval life table). Last,
all studies for the various access types/patency assess-
ments/anatomic locations were similarly used to create a
12-month interval life table. Failure rates were then calcu-
lated over each of the respective time intervals for these
aggregate 3-month, 6-month, and 12-month life tables,
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with the failure point between the respective consecutive
time intervals assumed to be the midpoint. Therefore esti-
mates for the failure points in the 3-month interval life table
were at 1.5, 4.5, 7.5, 10.5, 13.5, 16.5, 19.5, and 22.5
months. The corresponding failure points for the 6-month
interval life table were at 3, 9, 15, and 21 months, and those
for the 12-month interval life table were at 6 and 18
months. On the basis of these failure rates, cumulative
patency rate and standard error were calculated. An exam-
ple of aggregate data for primary patency of all PTFE
accesses (both forearm and upper arm) is shown in Appen-
dix 2 (online only). Comparisons of cumulative patency
curves were made at the various time points by assuming a
standard normal distribution and calculating z statistics.
Corrections were made for multiple comparisons with the
Bonferroni technique. P  .05 was considered significant.
RESULTS
The systematic review identified 34 studies that satis-
fied the inclusion criteria (Appendix 3, online only).3,9-41
Year of publication ranged from 1972 to 2001, with 76% of
studies published after 1990. The experimental design was
either a case series or a nonrandomized, controlled study in
most reports, and data were predominantly collected retro-
spectively. Five randomized, controlled trials were included
in the review. However, patients were not randomized
between autogenous and PTFE accesses in any of the
studies. Rather, they were randomized to receive different
types of grafts (standard PTFE vs stretch PTFE, standard
PTFE vs thin-wall PTFE, biologic vs PTFE), different
brands of PTFE grafts (Impra vs Gore), or modified PTFE
grafts (venous cuff vs no venous cuff). Indeed, only three
studies contained acceptable patency data for both autog-
enous and PTFE accesses. Study sample size ranged from
15 to 388 patients (median, 80 patients). Patency rate was
reported predominantly with the life table method, as
opposed to the Kaplan-Meier method, and was reported in
graphic format in slightly more than half of the reports.
Patient demographic data, comorbid conditions, and peri-
operative outcome were not always provided in the studies
that comprised the review (Appendix 4, online only). How-
ever, patients in the individual studies tended to be elderly
(median age, 57 years; range, 45-70 years), equally dis-
tributed by gender (male: median, 50%; range, 45%-64%),
and included a relatively high percentage of patients with
diabetes (median, 47%; range, 32%-68%). Lack of a stan-
dard reporting system limited the ability to combine many
of the complications. However, results of the individual
studies suggest that perioperative mortality was essentially
zero (median, 0; range, 0%-1%), whereas incidence of hand
ischemia (median, 2%; range, 0%-14%), accesses infection
(median, 7%; range, 0%-30%), and aneurysm or pseudoan-
eurysm formation (median, 4%; range, 0%-6%) was low for
both autogenous and PTFE accesses. Of note, the over-
whelming majority of access infections were found in PTFE
accesses.
Both the primary and secondary patency rates for au-
togenous accesses were significantly greater than for PTFE
accesses at all time points analyzed, with the one noted
exception of the initial time point (1.5 months) for the
primary patency comparison (Fig; Table). Notably, the
primary patency rate for autogenous accesses was 72% (95%
confidence interval [CI], 70%-74%) at 6 months, and 51%
(95% CI, 48%-53%) at 18 months, and the corresponding
primary patency rate for PTFE accesses was 58% (95% CI,
56%-61%) and 33% (95% CI, 31%-36%) respectively. Com-
parable differences were also seen for the secondary patency
rates at both 6 months (autogenous, 86%; 95% CI, 84%-
88% vs PTFE, 76%; 95% CI, 73%-79%) and 18 months
(autogenous, 77%; 95% CI, 74-79% vs PTFE, 55%; 95% CI,
51%-59%). Predictably, the secondary patency rates for
both autogenous and PTFE access types were significantly
Breakdown of autogenous and PTFE hemodialysis accesses by location
Fistula/patency end point
Initial no.
at risk
Patency
6 mo 18 mo
% 95% CI % 95% CI
All autogenous, primary 1849 72 70-74*† 51 48-53*†
All autogenous, secondary 1336 86 84-88† 77 74-79†
All PTFE, primary 1245 58 56-61* 33 31-36*
All PTFE, secondary 703 76 73-79 55 51-59
Forearm autogenous, primary 1325 71 69-73*† 49 47-52*†
Forearm autogenous, secondary 641 91 89-93† 86 83-89†
Forearm PTFE, primary 537 51 48-54* 28 25-32*
Forearm PTFE, secondary 330 69 65-73 47 42-52
Upper arm autogenous, primary 286 81 77-85 60 53-67‡
Upper arm autogenous, secondary 280 NA NA
Upper arm PTFE, primary 431 69 66-73‡ 49 45-54‡
Upper arm PTFE, secondary 270 NA NA
NA, Not applicable; insufficient data at specific time point.
*Significant difference between primary and secondary patency for specific access type.
†Significant difference between autogenous/PTFE for the specific patency assessment.
‡Significant difference between upper arm/forearm for the specific access type and patency assessment.
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greater than the corresponding primary patency rates. Of
interest, the primary patency rates for autogenous arterio-
venous accesses were comparable to secondary patency rate
for PTFE accesses.
Subset analysis of patients with forearm and upper arm
accesses revealed many of the same trends (Table). The
primary and secondary patency rates for forearm autoge-
nous accesses were significantly greater than for the corre-
sponding PTFE accesses at both 6 and 18 months. The
primary patency rates for autogenous upper arm accesses
were also significantly greater than for PTFE grafts at 6
months, and the difference approached significance at 18
months (P  .06). Comparison of the secondary patency
rate for upper arm accesses at both 6 and 18 months was
not possible, because of insufficient data. Of interest, pri-
mary patency rates for both autogenous and PTFE upper
arm accesses were significantly greater than for correspond-
ing forearm accesses at both 6 and 18 months.
DISCUSSION
The results of the current study confirm the prevailing
opinion that patency rates for autogenous upper-extremity
hemodialysis accesses are significantly better than for PTFE
counterparts. The supporting data represent the “best pos-
sible evidence” from the literature, and are composed of a
meta-analysis of 34 studies in which accesseses patency was
reported, using life table analysis or the Kaplan-Meier
method. The strength of these observations and data are
reinforced by the large sample size and the fact that they
represent an aggregate of access configurations and patient
comorbid conditions without significant selection bias, be-
cause no a priori criteria were incorporated in the study to
exclude either configurations or patients (eg, repeat oper-
ative procedure, diabetes, human immunodeficiency virus)
potentially at higher risk for access failure.
The patency data represent the “best possible evi-
dence” from the literature. However, the overall quality of
the individual studies that comprised the meta-analysis was
not good by evidence-based medicine standards, with the
overwhelming majority representing the lowest level of
evidence (case series). It is ironic that a large percentage of
included studies were retrospective case reports, because
inclusion of similar “marginal” studies as documentation
for superior patency rate of autogenous accesses according
to NKF/DOQI guidelines provided one impetus for this
review. In our original study design, the search strategy
involved a tiered approach that linked the search terms to
study qualifiers (eg, meta-analysis; randomized, controlled
trial). We had hoped to perform a sensitivity analysis and
present the patency data in separate groups based on hier-
archy of study design (meta-analysis; randomized, con-
trolled trial; cohort study; case-control study; case series) or
study characteristics (eg, publication date, both primary
and secondary patency reported, both autogenous and
PTFE accesses patency reported). However, this was not
feasible because of limitations of the published studies
Patency rate (percent patent) for autogenous (Auto) and polytetrafluoroethylene (PTFE) upper extremity arteriovenous hemodialysis
accesses plotted against time (months), with positive standard error bars. Both primary (Auto 1, PTFE 1) and secondary (Auto 2, PTFE 2)
patency rates for the two access types are shown. Patency rates for autogenous accesses are better than for their corresponding PTFE
counterparts, with the one exception of the initial (1.5 months) time point for primary patency comparison.
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identified. Importantly, our requirement that accesses pa-
tency had to be reported with either life table or Kaplan-
Meier method, with the number of patients at risk, in part
overcomes the limitations of overall study quality and lends
itself to the meta-analysis. The life table method is the gold
standard for reporting patency after revascularization pro-
cedures and enables presentation of data for patients un-
dergoing procedures at different times with different fol-
low-up duration.8 The method allows graft failures to be
grouped into specific time intervals that can be used to
calculate interval survival rate and cumulative patency rate.
Patients lost to follow-up (censored data) are withdrawn at
the midpoint of the time interval, and factor into the
interval failure rate. Although both the life table and
Kaplan-Meier method are good for estimating patency,
they potentially overestimate “true” patency rate, since it
has been reported that outcome in patients lost to fol-
low-up is not so favorable as for patients with known
follow-up data.42
It is conceivable that our search strategy failed to iden-
tify every possible appropriate study and is therefore poten-
tially subject to several criticisms. Other electronic data-
bases are available, such as Embase, that we could have
used. However, our library system does not currently have
accesses to these other databases, and single user cost was
prohibitive. It is possible that the search terms were too
strict and that appropriate articles were not identified be-
cause the life table or Kaplan-Meier terms were not in-
cluded in the abstract of the article or among the key words.
Furthermore, our search was restricted to full-text articles
written in English. The requirement for full-text articles is
justified by the need to critically appraise the method and
results of the individual studies in an attempt to determine
the suitability of the life table or Kaplan-Meier data. Lim-
iting the search to articles written in English is potentially
problematic because it is generally accepted that the rate of
autogenous arteriovenous accesses use for permanent he-
modialysis accesses is higher outside the United States.
However, cost and the practicality of finding appropriate
translators were prohibitive. Despite these limitations, it is
unlikely that our search missed many relevant articles, and it
is even less likely that including these potentially missed
articles in our meta-analysis would have affected the results.
It is difficult to imagine that a “definitive” article about
hemodialysis accesses patency was not included in the
DOQI guidelines or one of the hemodialysis texts, regard-
less of the language of origin. Furthermore, sample sizes in
the meta-analysis were so large and the respective standard
errors (confidence intervals) so small that even several
additional studies would not likely have altered the patency
curves.
The superior patency rates suggest that autogenous
arteriovenous accesses should be the initial choice for per-
manent hemodialysis access. However, patency is only one
of several determinants that factor into the clinical decision
regarding the most appropriate accesses choice. These ad-
ditional factors potentially include life expectancy, patient
preference, cost, number of revisions to maintain accesses
patency, the amount of time that temporary accesses cath-
eters are required (and their associated complications), the
duration from operative procedure until access is sufficient
for cannulation, and postoperative complications. We did
attempt to define complication rate, but were unable to
extract data for several of these clinically relevant factors
because they were rarely reported. Furthermore, complica-
tion rates reported in most studies were somewhat suspect
and not amenable to meta-analysis because no standard
reporting system was in place at the time of their publica-
tion. In addition, most of the studies reported complica-
tions rate in terms of incidence (patients experiencing event
per total number of patients), although this is potentially
misleading because it fails to account for the duration of
time in which the access was functional. Ideally, complica-
tions should be defined in terms of number of events per
patient-year at risk. The Society for Vascular Surgery and
The American Association for Vascular Surgery have re-
cently established reporting standards for arteriovenous
hemodialysis access that may resolve some of these difficul-
ties, and they include a grading system for both complica-
tions and clinical factors that potentially affect outcome.43
Several features of the systematic review merit further
comment. The stated purpose of the study was to examine
the differences in “functional patency” between autoge-
nous and prosthetic accesses. As noted in the Methods
section, there is a significant difference between primary
patency and functional primary patency. Indeed, recent
reporting standards define an access as functional when it is
able to sustain a flow rate of 350 to 400 mL/min for 4
hours.43 Similar, strict criteria were not available for the
studies that composed the systematic review, and we were
forced to use the various authors’ criteria for nonfunctional
access. Furthermore, it is conceivable that the patency rate
for the autogenous accesses overestimates the true value.
Accurate assessment requires that patient data be analyzed
on the basis of “intent to treat” and that all accesses that do
not mature sufficiently for cannulation be considered fail-
ures. Indeed, failure of autogenous accesses to mature has
been described as a major limitation of their use. It should
be noted that the life table data in the various studies that
composed the review were deemed acceptable only if it was
possible to account for all patients, although it is conceiv-
able that patients whose accesses failed to mature were
excluded. The current study demonstrated that approxi-
mately 17% of autogenous accesses failed within the first 3
months. Of interest, this number is almost identical to that
reported from our study validating a prospective algorithm
designed to increase the use of autogenous accesses44 and is
well within the range reported in the literature.
Meta-analysis of the life table data was complicated in
that the individual studies reported their outcomes in dif-
ferent time intervals. Essentially all of the studies reported
12-month and 24-month patency rates with the appropri-
ate number of patients at risk. However, these two time
points alone are not nearly as informative as patency curves
generated with more frequent intervals. We attempted to
overcome these limitations by combining the data into
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shorter intervals when possible. This compilation of the
data into shorter intervals was predicated on the assump-
tion that graft failures occurred at the midpoint of the
interval. Although somewhat simplistic, this assumption
seems valid from a statistical standpoint and does not likely
overestimate true patency rate. Our technique did not
allow us to report the number of patients at risk for failure
at various time intervals beyond the initial interval. Finally,
22.5 months was the last time point reported for access
patency, both because of the assumption we made that
failure occurred at the midportion of the interval (22.5
months, midway between 21 and 24 months) and because
the data reported after 24 months in the individual studies
were incomplete. It is impossible to determine patency of
the access types beyond 22.5 months, given the data pre-
sented, although it is likely that the observed patency
advantage for autogenous accesses would continue.
CONCLUSION
Patency rate for autogenous upper extremity arterio-
venous hemodialysis accesses appears to be superior to that
for their PTFE counterparts, given the “best available evi-
dence” in the literature. However, the overall quality of the
studies that composed the meta-analysis was less than ideal,
by the standards of evidence-based medicine. Randomized,
controlled trials comparing autogenous and PTFE hemo-
dialysis accesses are necessary to examine differences in
patency and other relevant outcome measures. The impor-
tance of these trials is underscored by the magnitude of the
clinical problem, both in the United States and abroad.
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APPENDIXES
Appendix 1, online only. References for systematic
review
Electronic database.
Medline, 1966–July 2001
Hemodialysis access textbooks.
Conlon PJ, Nicholson ML, Schwab S, editors. Hemo-
dialysis vascular access: practice and problems.
Wilson SE, editor. Vascular access principles and prac-
tice. 3rd ed.
Sommer BG, Henry ML, editors. Vascular access for
hemodialysis.
Sommer BG, Henry ML, editors. Vascular access for
hemodialysis: II.
Henry ML, Ferguson RM, editors. Vascular access for
hemodialysis: III.
Henry ML, Ferguson RM, editors. Vascular access for
hemodialysis: IV.
Henry ML, Ferguson RM, editors. Vascular access for
hemodialysis: V.
Henry ML, editor. Vascular access for hemodialysis:
VI.
Henry ML, editor. Vascular access for hemodialysis:
VII.
Vascular surgery textbooks.
Ernst CB, Stanley JC, editors. Current therapy in vas-
cular surgery. 4th ed.
Moore WS, editor. Vascular surgery: a comprehensive
review. 5th ed.
Rutherford RB, editor. Vascular surgery. 5th ed.
General surgery textbooks.
Schwartz SI, editor. Principles of surgery. 7th ed.
Townsend CM, Sabiston DC, editors. Sabiston text-
book of surgery: the biological basis of modern surgical
practice. 16th ed.
Greenfield LJ, editor. Surgery: scientific principles and
practice. 3rd ed.
Appendix 2, online only. PTFE primary patency
Interval (mo)
No. at risk
Failure interval
Failure
rateNo. at risk
Begin
interval
0-3 559 82 28 0.1504587
0-6 1030 271 156 0.2846639
3-6 449 47 34 0.1087963
0-12 1245 466 294 0.424408
6-9 368 32 21 0.0895105
6-12 603 105 86 0.1875
9-12 315 26 23 0.0856672
12-15 266 12 133 0.0601504
12-18 412 43 165 0.1305008
15-18 121 8 14 0.0701754
12-24 487 106 248 0.292011
18-21 99 6 7 0.0628272
18-24 204 21 65 0.122449
21-24 86 7 21 0.0927152
0-6 1030 271 156 0.2846639
6-12 603 105 86 0.1875
12-18 412 43 165 0.1305008
18-24 204 21 65 0.122449
0-12 1245 466 294 0.424408
12-24 487 106 248 0.292011
Pooled data
month
Failure
rate Cumulative patency Standard error
1.5 0.150458716 0.849541284 0.01393758 82.222363 87.68589341
3 0.142331933 0.728624431 0.01182689 70.544373 75.18051322
4.5 0.108796296 0.649352792 0.01814649 61.378566 68.49199205
6 0.106102004 0.58045516 0.01065548 55.957041 60.13399088
7.5 0.08951049 0.528498334 0.01891739 49.142024 56.55764281
9 0.09375 0.478951615 0.01407901 45.135676 50.65464683
10.5 0.085667216 0.437921164 0.01849862 40.166387 47.41784543
13.5 0.060150376 0.411580041 0.01935785 37.363865 44.9521433
15 0.065250379 0.384724287 0.01486743 35.558413 41.38644489
16.5 0.070175439 0.357726092 0.02606262 30.664336 40.88088271
18 0.073002755 0.331611102 0.01228511 30.753228 35.56899253
19.5 0.062827225 0.310776896 0.02593051 25.99531 36.16006939
21 0.06122449 0.291749739 0.01719051 25.805634 32.54431392
22.5 0.092715232 0.264700095 0.02447581 21.67275 31.26726881
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Appendix 3, online only. Study description
Author Reference Study question Study design
Ascher Ann Vasc Surg 2001;15:89 Autogenous brachiobasilic vs brachiocephalic fistula Controlled
Lemson J Vasc Surg 2000;32:1155 Effect of venous anastomotic cuff on PTFE access Randomized,
controlled
Staramos Eur J Surg 2000;166:777 Autogenous vs PTFE accesses in patients 69 y Controlled
Matsuura Ann Vasc Surg 2000;14:50 Cadaveric superficial femoral vein vs PTFE accesses Controlled
Kalman J Vasc Surg 1999;30:727 Efect of access program and coordinator Controlled
Curi J Vasc Surg 1999;29:608 Autogenous vs PTFE access in patients HIV/HIV Controlled
Hurlbert Cardiovasc Surg 1998;6:652 Gore PTFE vs Impra PTFE accesses Controlled
Matsuura Am J Surg 1998;176:219 Autogenous brachiobasilic vs PTFE brachioaxillary accesses Controlled
Lenz J Vasc Surg 1998;28:464 Standard vs thin-wall PTFE accesses Randomized,
controlled
Silva J Vasc Surg 1998;27:304 Effect of algorithm to increase autogenous accesses Controlled
Silva J Vasc Surg 1997;26:981 Autogenous forearm accesses Case series
Kaufman J Am Coll Surg 1997;185:74 Gore PTFE vs Impra PTFE accesses Randomized,
controlled
Hakaim J Vasc Surg 1997;25:1002 Early vs late cannulation of PTFE accesses Controlled
Miller Ann Vasc Surg 1997;11:397 Effect of algorithm to increase autogenous accesses Controlled
Yasuhara Ann J Surg 1997;174:83 Effect of revision on autogenous radiocephalic accesses Case series
Wang Artif Organs 1996;20:1278 Biologic vs PTFE accesses Controlled
Leapman Am Surg 1996;62:652 Autogenous Radiocephalic accesses Case series
Bender Eur J Vasc Endovasc Surg 1995;10:294 Median antecubital vs brachiocephalic autogenous accesses Controlled
Tordoir Eur J Vasc Endovasc Surg 1995;305 Standard vs stretch PTFE accesses Randomized,
controlled
Burger Eur J Surg 1995;161:327 Comparison of different hemodialysis accesses Controlled
Polo Artif Organs 1995;19:181 Brachioaxillary PTFE accesses Case series
Elcheroth Br J Surg 1994;81:982 Autogenous upper arm access Case series
Simoni Cardiovasc Surg 1994;2:63 Snuffbox vs wrist autogenous radiocephalic accesses Controlled
Rivers J Vasc Surg 1993;18:391 Autogenous brachiobasilic accesses Case series
Rubens Cardiovasc Surg 1993;1:128 Autogenous brachiocephalic accesses Case series
Hibberd Aust N Z J Surg 1991;61:631 Autogenous brachiobasilic acesses Case series
Schanzer Am J Surg 1989;158:117 PTFE vs PTFE-silicone accesses Controlled
Dunlop Ann R Coll Surg Engl 1986;68:203 Autogenous brachiocephalic accesses Case series
Munda JAMA 1983;249:219 PTFE accesses Case series
Salmon Can J Surg 1981;24:59 Biologic vs Gore PTFE accesses Controlled
Rapaport Aust N Z J Surg 1981;51:562 PTFE accesses Case series
Bone J Surg Res 1980;29:223 Biologic vs PTFE accesses Randomized,
controlled
Haimov J Cardiovasc Surg 1980;21:149 Biologic vs saphenous vein vs PTFE accesses Controlled
Haimov Proc Eur Dial Transplant Assoc 1972;9:173 Autogenous radiocephalic accesses Case series
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Data collection Access type included Sample size Patency assessment Source of patency data
Retrospective Autogenous 172 Kaplan-Meier Table
Retrospective PTFE 61 Life table Graph
Retrospective Autogenous 68 Kaplan-Meier Table
Retrospective PTFE 68 Life table Table
Prospective Autogenous, PTFE Autogenous, 239; PTFE, 215 Kaplan-Meier Graph
Retrospective Autogenous, PTFE Autogenous-55, PTFE-57 Life table Table
Prospective PTFE 190 Life table Table
Retrospective Autogenous 30 Kaplan-Meier Graph
Prospective PTFE 108 Life table Table
Prospective Autogenous, PTFE Autogenous-108, PTFE-52 Life table Table
Retrospective Autogenous 89 Life table Table
Prospective PTFE 129 Life table Table
Prospective PTFE 79 Kaplan-Meier Table
Retrospective Autogenous 75 Kaplan-Meier Table
Retrospective Autogenous 283 Life table Graph
Retrospective PTFE 34 Kaplan-Meier Graph
Retrospective Autogenous 150 Kaplan-Meier Graph
Retrospective Autogenous 73 Life table Graph
Prospective PTFE 37 Life table Graph
Retrospective Autogenous 208 Kaplan-Meier Graph
Prospective PTFE 157 Life table Graph
Retrospective Autogenous 272 Life table Graph
Retrospective Autogenous 388 Kaplan-Meier Graph
Retrospective Autogenous 65 Life table Table
Retrospective Autogenous 16 Life table Graph
Prospective Autogenous 15 Life table Table
Retrospective PTFE 35 Life table Graph
Retrospective Autogenous 81 Life table Graph
Retrospective PTFE 67 Life table Graph
Retrospective PTFE 42 Life table Graph
Retrospective PTFE 103 Life table Table
Prospective PTFE 20 Life table Graph
Retrospective PTFE 22 Life table Table
Retrospective Autogenous 203 Life table Table
PTFE, Polytetrafluoroethylene.
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Appendix 4, online only. Study outcome
Author Reference Access type
Group
size
Age (y)
Mean SD
Ascher Ann Vasc Surg 2001;15:89 Upper arm autogenous, brachiocephalic 109 67 1.4
Upper arm autogenous, brachiobasilic 63 69 2.0
Lemson J Vasc Surg 2000;32:1155 Forearm PTFE 61 63 2
Staramos Eur J Surg 2000;166;777 Forearm/upper arm autogenous 68 70
Matsuura Ann Vasc Surg 2000;14:50 Upper arm PTFE 68 62
Kalman J Vasc Surg 1999;30:727 Forearm/upper arm fistula 239
Forearm/upper arm PTFE 215
Curi J Vasc Surg 1999;29:608 Forearm/upper arm PTFE, HIV 27
Forearm/upper arm PTFE, HIV 30
Forearm/upper arm autogenous, HIV 23
Forearm/upper arm autogenous, HIV 32
Hurlbert Cardiovasc Surg 1998;6:652 Forearm/upper arm PTFE, Impra 90 63
Forearm/upper arm PTFE, Gore 100 64
Matsuura Am J Surg 1998;176:219 Upper arm autogenous 30 59
Lenz J Vasc Surg 1998;28:464 Forearm PTFE, standard wall 56 54
Forearm PTFE, thin wall 52 55
Silva J Vasc Surg 1998;27:304 Forearm/upper arm autogenous 108
Forearm/upper arm PTFE 52
Silva J Vasc Surg 1997;26:981 Forearm autogenous 89 62
Kaufman J Am Coll Surg 1997;185:74 Forearm PTFE, Gore 64
Forearm PTFE, Impra 65
Hakaim J Vasc Surg 1997;25:1002 Upper arm PTFE, early cannulation 48 61 3
Upper arm PTFE, late cannulation 31 62 4
Miller Ann Vasc Surg 197;11:397 Forearm/upper arm autogenous 75
Yasuhara Am J Surg 1997;174:83 Forearm autogenous 283 56
Wang Artif Organs 1996;20:1278 Forearm PTFE 34
Leapman Am Surg 1996;62:652 Forearm autogenous 150 50 16
Bender Eur J Vasc Endovasc Surg 1995;10:294 Upper arm autogenous 73 61 median
TORDOIR Eur J Vasc Endovasc Surg 1995;305 Forearm PTFE, standard wall 20 58
Forearm PTFE, stretch 17 59
Burger Eur J Surg 1995;161:327 Forearm autogenous 208
Polo Artif Organs 1995;19:1181 Upper arm PTFE 157 50
Elcheroth Br J Surg 1994;81:982 Upper arm autogenous 272
Simoni Cardiovasc Surg 1994;2:63 Wrist autogenous 248 53
Snuffbox autogenous 140 51
Rivers J Vasc Surg 1993;18:391 Upper arm autogenous 65 47
Rubens Cardiovasc Surg 1993;1:128 Upper arm autogenous 16
Hibberd Aust N Z J Surg 1991;61:631 Upper arm autogenous 15 54
Simoni Cardiovasc Surg 1994;2:63 Wrist autogenous 248 53
Snuffbox autogenous 140 51
Rivers J Vasc Surg 1993;18:391 Upper arm autogenous 65 47
Rubens Cardiovasc Surg 1993;1:128 Upper arm autogenous 16
Hibberd Aust N Z J Surg 1991;61:631 Upper arm autogenous 15 54
Schanzer Am J Surg 1989;158:117 Upper arm PTFE 35 57
Dunlop Ann R Coll Surg Engl 1986;68:203 Upper arm autogenous 81 45
Munda JAMA 1983;249:219 Forearm/upper arm PTFE 67 58
Salmon Can J Surg 1981;24:59 Forearm shunt, Gore 14 45
Forearm shunt, Impra 28 46
Rapaport Aust N Z J Surg 1981;51:562 Forearm/upper arm PTFE 103 48
Bone J Surg Res 1980;29:223 Forearm PTFE 20 53
Haimov J Cardiovasc Surg 1980;21:149 Forearm PTFE 22
Haimov Proc Eur Dial Transplant Assoc 1972;9:173 Radiocephalic autogenous 203
PTFE, Polytetrafluoroethylene.
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Male
(%)
Diabetes
(%)
Previous
permanent
access (%)
Postoperative
death (%)
Hand ischemia
(%)
Graft infection
(%)
Aneurysm/
pseudoaneurysm
(%)
37 56 0 1
40 65 5 0
48 35 46 0 0.01 pt/y 0.02 pt/y
78 32 0
53 47 0 3 12 3
30
7
9
0
48 33 2 3
40 43 3 9
47 64 0 0
48 2 6
50 3 5
0 0 1
2 12 4
60 0 0 0
6 11
6 14
48 61 83 0
100 55 81 0
1 1
64
73 34 0 5
47 53 0 1 1
60 36 0 5 10 5
29 43 0 6 6 0
83 1 early, 0.01 pt/y late 1 early, 0.06 pt/y late 0.02 pt/y
42 52 14 5 4
54 0 0
65 0 0
43 75 0 2 4
6 6
7 66 0 7 7 7
54 0 0
65 0 0
43 75 0 2 4
6 6
7 66 0 7 7 7
68 40 0 11 17
48 4 2 4
31 85 3 25 8
0 0 7 7
0 0 4 4
61
100 45 10 0
PTFE, Polytetrafluoroethylene.
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